Loading
A phase 3 trial of Docetaxel in triple-negative breast cancer, run by Jina Pharmaceuticals Inc., now recruiting.
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients is a phase 3 interventional study registered as NCT03671044 by Jina Pharmaceuticals Inc., with 657 participants planned, started 2018-07-10 and due to reach its primary completion in 2025-05-31. Interventions recorded: Nanosomal Docetaxel Lipid Suspension (75 mg/m2), Nanosomal Docetaxel Lipid Suspension (100 mg/m2) and Taxotere® (100 mg/m2).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Shares Docetaxel, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/